Catalyst
Slingshot members are tracking this event:
Cidara (CDTX) Phase 2 RADIANT Data Evaluating Topical CD101 in Yeast Infection (Vulvovaginal Candidiasis VVC)
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
CDTX |
|
|
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 21, 2017
Occurred Source:
http://ir.cidara.com/phoenix.zhtml?c=253962&p=irol-newsArticle&ID=2247615
Related Projects
- With Phase 2 Data Expected in Q1, Where Does Cidara's (CDTX) Topical CD101 Stand in the Antifungal Market for Yeast Infection (Vulvovaginal Candidiasis VVC)? CDTX Executed On: Jan 27, 2017 at 02:00 PM EST
Related Keywords
Phase 2, Radiant, Topical, Cd101, Vvc, Vulvovaginal Candidiasis